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Abstract A retinal vein occlusion (RVO) is a sight
threatening disease. It can be divided into central vein
occlusion and branch retinal vein occlusion. The pathogen-
esis of the condition remains to be solved. Mechanical
compression of the vessel wall or thrombotic occlusion of
the vessel lumen, sometimes combined with rheological
disorders, are often assumed pathomechanisms. According-
ly, the therapy relies either on mechanical decompression,
lyses of thrombi or improvement of rheology. A number of
observations however, such as the relationship of RVO to
atherosclerotic risk factors, spontaneous reversibility par-
ticularly in young patients, rest flow observed in angiogra-
phy, occlusion despite anticoagulation or thrombocytopenia
and finally the positive effect of anti-VEGF therapy are not
explained by the present pathogenetic concept. As a new
concept we propose a local venous constriction induced by
vasoconstrictive molecules diffusing from neighbouring
diseased arteries and/or from other neighbouring (hypoxic)
tissues. Recognizing these postulated conditions might lead
to an earlier identification of impending vein occlusions as
well as to a treatment more tailored to the risk factor
constellation of the particular patient.
Keywords Retinal vein occlusion.BRVO.
Personalized treatment.Prevention.
Vascular dysregulation.Endothelin-1
Introduction
The German ophthalmologist Leber observed and described
the clinical picture of Retinal Vein Occlusion (RVO) [1]
about 150 years ago. RVO is the second most common
retinal vascular disorder often leading to severe loss of
visual function. Roughly, RVOs has been classified as
follows: The central retinal vein occlusion, the hemicentral
retinal vein occlusion and the branch retinal vein occlusion
(BRVO) [2], the latter being the most common type.
Although the mechanisms involved might be basically
similar in all these types, we shall focus here on BRVOs.
Until today, various pathogenetic mechanisms have been
described. Nevertheless, they all leave a number of
questions open.
The purpose of this paper is to summarize these
unanswered questions and to formulate a new hypothetic
concept considering these facts.
Present pathogenetic concepts
Mechanical compression of the vein
One of the first factors observed by Leber was both, the local
relationshipofBRVOstoarteriovenousA/Vcrossingsandthe
association with atherosclerosis. It was assumed that the vein
is compressed by the rigid artery [3]. It was hypothesized that
the over-crossed vein had no space to escape the pressure of
the thickened and atherosclerotic altered artery and is
compressed or that the vein becomes curved under the
pressure of the artery. Both would lead to a disturbed blood
flow and to a thrombosis. A common adventitia could fortify
this effect [4, 5]. The concept of mechanical compression is
supported by the observation that in case of BRVO, the
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vein [6–8].
Indeed, in patients with atherosclerosis and systemic
hypertension, a narrowing of the vein at the A/V crossing
and signs of turbulence of the blood flow are also visible in
fluorescence angiographies [9]. Further, multiple crossings
or loops as potential causes of an occlusion have been
described [10]. The association of glaucoma with RVOs
[11] supports an IOP induced mechanical compression of
the vein.
Finally, the so called sheathotomy is also based on the
idea of a mechanical compression and indeed, beneficial
effects have been described in some studies [12–14].
Sick vein
A proliferation and swelling of the endothelium as well as a
subintimal fibrosis has been described [15, 16]. A trophic
alteration of the vessel wall with disruption of the blood
flow followed by secondary thrombosis of the vessel lumen
was postulated.
Other authors however failed to find any pathological
altered veins [17].
Hemorheological alterations
The following parameters have been described in literature to
occur more often in RVO compared to controls: Anticoag-
ulant proteins, activated protein C resistance, factor V
Leiden mutation, antiphospholipid antibodies, anticardiolipin
antibodies, platelet aggregation disorders, hyperhomocystei-
nemia, high plasma viscosity and others [18]. Again, they
have been discussed controversially.
It is unknown whether such factors can induce RVOs by
themselves or if they are rather cofactors.
Open questions challenging the present concepts
The pathomechanisms described above raise some ques-
tions that are listed below:
1) If we assume the mechanical compression of the vein
being important:
Why is a BRVO sometimes reversible [19]?
Why do BRVOs not always occur at A/V crossings
[19]?
Why is a distinct vein compression histologically
not always visible [20]?
Why do we only extremely rarely find a thrombus
[4, 21, 22]? And if a thrombus is present why do
we find it rather downstream of A/V crossings
[23]? And if we assume that a thrombus is present,
why is the flow not completely interrupted in
fluorescence angiographies after BRVO?
Why is the capillary blood flow reduced in areas
not affected from BRVO [24]?
Why does BRVOs occur also in younger patients
without any signs of atherosclerosis [25]?
Why can we find elevated endothelin levels even
in young patients with BRVO [26–28]?
Why does emotional stress seem to be sometime a
trigger factor for the development of BRVO [25]?
2) If we consider a sick vein being a major cause:
Why do we find a risk factor constellation
similar to arterial diseases such as systemic
hypertension, diabetes mellitus, older age, dysli-
pidemia and smoking but unlike venous diseases
[29–32]?
Why does the accompanying retinal edema [33]
respond to VEGF inhibitors [34] when the edema
is believed to be due to back pressure?
Why is the association between systemic venous
thrombotic diseases and RVO extremely low? The
prevalence of venous disease in patients with
BRVO is approximately 3% [35].
Why do we, as mentioned before, only seldom find
a thrombus in RVOs?
3) If we consider a thrombus formation to be induced by
hemorheological alterations and/or alterations to the
coagulation cascade:
Why can BRVOs develop in patients with throm-
bocytopenia or under anticoagulation [18, 36, 37]?
Why are only thrombophilic factors associated
with RVOs, which are risk factors for both venous
thrombosis and arterial vascular disease (in other
parts of the body)? Risk factors for venous
thrombosis alone seem not to be important [38].
The concept of functional dysregulation of the vein
We propose a venous dysregulation to be the major
component for the development of RVOs. Such a dysregu-
lation implies both inadequate vasoconstriction and in-
creased vessel permeability. The latter, results from an
impaired blood-retinal barrier.
Before we discuss this new concept, we shall describe
some of the basic mechanisms for vascular regulation and
dysregulation:
Like elsewhere in the body the retinal arteries and
veins are highly regulated. In general the regulation of
arteries has attracted more attention [39, 40], although
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factors involved, two factors are of special interest in
this context: Endothelin-1 (ET-1) for vasoconstriction
[42] and the vascular endothelial growth factor
(VEGF) for vessel permeability [43].
The vasoactive substances are either produced locally
by the endothelial cells and by the surrounding tissue
or diffuse from the circulating blood to the smooth
muscle cells or pericytes. The influence of these
molecules depends upon the function of the blood-
retinal barrier. The close relationship between artery
and vein at the A/V crossing (Fig. 1a and b) facilitates
the diffusion of vasoactive substances from the
arterial wall directly to the vein.
Under normal conditions (Fig. 2), the endothelial cell
of the retinal arterioles and venules respectively
release a small amount of ET-1 intraluminally and a
larger amount abluminally influencing the local
vascular tone. Due to the size of the molecule (21
amino acid peptide) and due to the biological half-life
time (around 15 min), ET-1 acts mainly locally.
In (mostly younger) patients with primary vascular
dysregulation (PVD) [44] (Fig. 3), the arterial wall
produces (at least under certain circumstances) an
increased amount of ET-1. This increases both the ET-
1 concentration in the circulating blood [45] as well
as the ET-1 concentration in the surrounding tissue of
the artery. In extreme situations, particularly if the
artery lies back to back to the vein as in A/V
crossings, this may lead to a local vasoconstriction
of the vein.
Such an assumption is supported by the fact that an
obstruction of retinal vessels has been shown in
animals by endothelin injections in the posterior
chamber [46].
In atherosclerosis (Fig. 4), the endothelial cells of the
arteries synthesize more ET-1 than healthy normal
vessels [47]. In addition, cells of the surroundings of
Fig. 1 a Histological cut through an arterio-venous crossing in a
human retina. b Schematic drawing. 1. Artery, 2. Vein, 3. Adventitia,
4. Vascular endothelial cell layer (blue)
Fig. 2 Physiological condition: Endothelin-1 is produced by the
endothelium of the artery and the vein. This affects mainly the
underlying smooth muscle cells
Fig. 3 Vascular dysregulation: The endothelial cells of the artery
produce more Endothelin-1 than normal. The vein gets under the
influence of this messenger and reacts with a vasoconstriction
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also produce ET-1 [48]. Both lead to an increased ET-1
concentration in the neighbouring tissue. This may lead
to some constriction of the arteries but even more of
the adjacent veins. Veins respond at lower concen-
trations to vasoconstrictive molecules than arteries
[41]. And in addition ET-1 stimulates arterial wall
fibrosis further contributing to a narrowing of the vein.
The blood-retinal barrier is weekend by several
messengers such as ET-1 or VEGF (Fig. 5)[ 49].
Both, ET-1 and VEGF, are upregulated in hypoxic
tissues [50, 51] as it is the case in atherosclerosis [52]
through a hypoxia inducible factor-1α (HIF-1α)
driven cascade (see Fig. 6). These upregulations
indirectly point toward a hypoxia caused by arterial
dysfunction.
The concept of a functional dysregulation of the vein
gives answers to the following questions
Why is a BRVO often reversible?
Because the vein occlusion has a major functional
component: The resulting venous vasoconstriction
might fade, for example due to a decrease of the
concentration of local constricting factors. If the
vessel relaxes RVO resolves partially.
Why do BRVOs not always occur at A/V crossings?
Because veins might come under the influence of
vasoconstricting messengers produced by the artery
and adventitia independent of an A/V crossing in
areas where arteries and veins are close enough. And
in fact, in these cases the occlusion occurred at a point
where the artery and the vein were adjacent [53].
Why is a distinct vein compression histologically not
always visible?
The mechanical vein compression might just be a
cofactor in addition to the vasoconstriction described
above, sometimes present, sometimes not.
Why do we only extremely rarely find a thrombus?
Because the vein occlusion may be due to a functional
narrowing of the vein and a thrombus may be absent
or if present it might have been developed rather
secondary.
Fig. 4 Atherosclerosis: Due to alterations to the arterial wall and its
adventitia, Endothelin-1 is not only overexpressed in endothelial cells
but also additionally produced by the cells of the adventitia and by
other cells of the surroundings of the atherosclerotic arteries. As
consequence, the vein constricts and in extreme situation a RVO
results
Fig. 5 Hypoxic condition: a
Hypoxic tissue produces mes-
sengers such as VEGF leading
to impairment of tight junctions
and thereby weakening of the
blood-retinal barrier. This leads
to increased permeability of the
vessels with the development of
exudates, retinal edema and
leakage in the fluorescence an-
giography. b Obviously other
factors are involved as well. For
example MMP-9 can digest the
basal membrane which, together
with a weakened blood-retinal
barrier, even allows erythrocytes
to escape the lumen of the vessel
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downstream of A/V crossings?
Because the thrombus formation is secondary to the
functional narrowing of the vein due to hemodynamic
alterations downstream to the narrowing.
And if we assume that a thrombus is present, why is the
flow not completely interrupted in fluorescence angiogra-
phies after BRVO?
Because the local obstacle to blood flow is rather a
venous constriction than a thrombosis. Such a
constriction rarely leads to a total occlusion.
Why is the capillary blood flow reduced in areas not
affected from BRVO?
Why does the blood flow often remain decreased after the
recovery from a BRVO in the area of the former BRVO but
also in areas that are not affected and even in the fellow eye?
We assume the primary pathology being on the
arterial side leading more or less to hypoxia and
upregulation of certain vasoconstrictive messengers.
If the concentration of vasoactive factors normalize,
the underlying arterial disease (e.g. atherosclerosis) is
still present.
Why does BRVOs occur also in younger patients
without any signs of atherosclerosis?
Why can we find elevated endothelin levels even in
young patients with BRVO?
Why does emotional stress seem to be sometime a
trigger factor for the development of BRVO?
In patients with PVD, we find a higher basal ET-1
concentration in the blood than in healthy non-PVD
subjects [45]. They often have systemic hypotension
[54].
As blood pressure drops, the ET-1 sensitivity
increases in subjects with PVD but not so in non-
PVD subjects [55].
ET-1 levels increase more in these subjects in
situations of emotional stress [56].
In young patients where other risk factors such as
atherosclerosis are absent, it is probably a pure
functional vasoconstriction triggering the cascade
leading to the clinical picture of RVOs.
Why do we find a risk factor constellation similar to
arterial diseases such as systemic hypertension, diabetes
mellitus, older age, dyslipidemia and smoking but unlike
venous diseases?
Because the risk factors for atherosclerosis lead to
altered arteries. The endothelial cells of these arteries
and the hypoxic surrounding tissues produce an
increased amount of local vasoconstrictors.
Why does the accompanying retinal edema respond to
VEGF inhibitors when the edema is believed to be due to
back pressure?
As a consequence of hypoxia in RVOs, several factors
such as VEGF might be upregulated. VEGF is known
to cause an impairment of the blood- retinal barrier.
As a consequence retinal edema is treatable with
VEGF inhibitors.
Why is the association between systemic venous
thrombotic disease and RVO extremely low?
Because a thrombus might be absent and if present it
might be due to the narrowing of the vein and rarely a
primary event.
If we assume a thrombus, why can BRVOs develop in
patients with thrombocytopenia or under anticoagulation?
Fig. 6 Induction of hypoxia in-
duced messengers: Hypoxia-
inducible factor-1α (HIF-1α)i s
constitutively produced. In situa-
tions with a normal O2 concen-
tration in the tissue, HIF-1α is
hydroxylated, ubiquitinated and
degraded by the proteosome. In
case of hypoxia however, HIF-
1α is less hydroxylated and
reaches the nucleus where it
promotes the expression of other
factors such as VEGF, Erythro-
poietin or ET-1
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for the development of RVOs. A temporal interrup-
tion of the blood flow due to a functional narrowing
of the vessel might be sufficient for the development
of the clinical picture of RVO.
Why are only thrombophilic factors associated with
RVOs, which are risk factors for both venous thrombosis
and arterial vascular disease (in other parts of the body)?
Risk factors for venous thrombosis alone seem not to be
important?
Because we postulate a cascade driven by ischemic
tissues with a primary pathology of the arteries that
secondary influences the vein. An altered arterial
vessel wall as well as an hypoxic surrounding tissue
might be responsible for an enhanced local endothelin
production.
Does the success of sheathotomy indicate mechanical
compression?
After surgical separation of the artery from the vein,
the vein is separated from the artery at a larger distance
and is therefore less influenced by the local messen-
gers. In addition, vitrectomy reduces the retinal
hypoxia [57] and thereby reduces the production of
vasoactive molecules in the surrounding tissue.
Why is RVO and glaucoma often associated?
RVO occurs more often in glaucoma patients. This
can be explained by the fact that RVOs and glaucoma
have some risk factors in common leading to the
assumption that the two diseases may be
interconnected [58]. The corresponding risk factors
however seem more pronounced in RVO than in
glaucoma:
On the molecular biological level, both in glaucoma as
well as in RVOs, substances such as HIF-1α [59], ET-1
[27][ 60], VEGF [33, 61, 62] or Erythropoietin [63, 64]
are increased.
On the more physical level, the upregulated substances
m a yl e a dt ob o t hav a s o c o n s t r i c t i o n[ 65]a n da
weakening of the blood-retinal barrier [66]. In glauco-
ma the factors mentioned above diffuse from the
fenestrated choroid to the optic nerve head (ONH).
Therefore, vasoconstriction occurs particularly in the
peripapillar region [65, 67, 68]. The impaired blood-
retinal barrier is visible as increased leakage of the
ONH in fluorescence angiography [66] or in extreme
cases even as splinter hemorrhages [69, 70].
The venous pressure is increased in both conditions.
This can be observed by an increased ophthalmodyna-
mometric force required inducing venous pulsation and
the fewer appearance of spontaneous venous pulsations
in glaucoma [71] and RVOs [72].
On the level of aetiology, in both diseases risk factors
such as an increased IOP, primary vascular dysregula-
tion [73] and sleep apnea [74, 75] seem to play a role.
Interestingly, increased levels of ET-1 have been found
in patients with PVD and sleep apnea as well as in
animal models with elevated IOP [45, 76–78].
All these factors together sufficiently explain the
relationship between glaucoma and RVO.
Conclusion
About one decade ago, we described primary vascular
dysregulation(PVD)asariskfactorforglaucomatousdamage.
In the present paper we describe a dysregulation of the vein as
a component for the pathogenesis of retinal vein occlusions.
While the pathophysiological concepts of RVOs de-
scribed in the literature so far, cover some aspects of the
disease, they are not totally sufficient to explain all
phenomena and aspects. Our concept is based on the
assumption that we are dealing less with a primary
structural pathology of the vein but rather with a functional
constriction of the vein. This, in turn, may be secondary
due to a change of the arterial vessel wall and/or due to the
hypoxic surrounding tissue. Hypoxia induces the upregula-
tion of factors that constrict veins. They may also contribute
to the impairment of the blood-retinal barrier leading to
oedema and in extreme cases even to hemorrhages.
This concept also explains the relation between RVOs and
other diseases including atherosclerosis, glaucoma and PVD.
Further studies are needed to confirm or reject this new
concept.
Outlook
In order to prevent vein occlusions we try to predict such an
event with the help of biomarkers. In the present manu-
script we describe the vascular dysregulation as a major risk
factor and biomarker for vein occlusions. Vascular dysre-
gulation can be recognized based on patient’s history (e.g.
often cold hands and feet), on clinical examinations (e.g.
reduced neurovascular coupling) or laboratory findings
(e.g. altered gene expression in lymphocytes).
While we are still in an early stage in search of the
relationship between vascular dysregulation and vein
occlusions, more information is already available about
the relationship between vascular dysregulation and glau-
coma [79–81]. The identification of vascular dysregulation
in glaucoma patients leads already to a more personalized
258 EPMA Journal (2010) 1:253–261therapy: Glaucoma patients with vascular dysregulation
benefit e.g. from an antivasospastic therapy such as calcium
channel blockers [82] in addition to the standard intraocular
pressure lowering therapy.
A better understanding of the pathophysiology of RVOs
and more specific biomarkers related to the individual risk
will bring a personalized therapy within reach.
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